Evidence map›Paper›PMID 35069810›Full record

ArticleTherapeutic advances in musculoskeletal disease2022

Poor health and functioning in patients with axial spondyloarthritis during the COVID-19 pandemic and lockdown: REUMAVID study (phase 1).

Diego Benavent, Marco Garrido-Cumbrera, Chamaida Plasencia-Rodríguez, Helena Marzo-Ortega, Laura Christen, José Correa-Fernández, Pedro Plazuelo-Ramos, Dale Webb, Victoria Navarro-Compán

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in musculoskeletal disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Diego BenaventRheumatology Service, IdiPAZ, La Paz University Hospital, Paseo de la Castellana, 261, Madrid 28046, Spain.ORCID https://orcid.org/0000-0001-9119-5330
Marco Garrido-CumbreraHealth & Territory Research, Universidad de Sevilla, Seville, Spain.
Chamaida Plasencia-RodríguezRheumatology Service, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Helena Marzo-OrtegaNIHR Leeds Biomedical Research Centre, LTHT and LIRMM, University of Leeds, Leeds, UK.
Laura ChristenNovartis Pharma AG, Basel, Switzerland.
José Correa-FernándezHealth & Territory Research, Universidad de Sevilla, Seville, Spain.
Pedro Plazuelo-RamosSpanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain.
Dale WebbNASS, London, UK.
Victoria Navarro-CompánRheumatology Service, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Hospital Universitario La Paz · ESUniversidad de Sevilla · ESNovartis (Switzerland) · CHThe National Autistic Society · GBUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the overall health and functioning in patients with axial spondyloarthritis (axSpA) and related factors affecting these during the COVID-19 pandemic and lockdown measures.

methodsData from 587 axSpA patients participating in the first phase (April-July 2020) of the REUMAVID study who completed the ASAS Health Index (ASAS-HI) were analysed. REUMAVID is a cross-sectional study that collects data through an online survey to assess the impact of the COVID-19 pandemic on patients with rheumatic and musculoskeletal diseases across seven European countries. Poor health was defined as ASAS-HI ⩾ 12. The World Health Organization Five well-being index, self-perceived health status and change in health status during COVID-19 pandemic were evaluated as secondary outcomes. Logistic regression models were used to identify the factors associated with poor health.

resultsAccording to the ASAS-HI, 147 (25.0%) patients reported poor health. Pain and moving around were the main affected categories. In addition, 14.0% reported their self-perceived health status as 'bad' or 'very bad' and 46.8% as worse than before the pandemic. In the multivariate analysis, smoking (OR = 1.98), diabetes (OR = 4.89) and taking painkillers (OR = 2.82) or corticosteroids use (OR = 2.20) were significantly associated with poor health, while engaging in physical activity (OR = 0.54) and being actively employed (OR = 0.48) were inversely associated with this.

conclusionsDuring the first wave of the COVID-19 pandemic, one in four axSpA patients reported poor health and functioning, while the self-perceived health status of almost half of these patients worsened. Nonsmoking, physical activity and being employed were associated with better outcomes.

Indexed as

ASAS-HIaxial spondyloarthritisCOVID-19pandemicpatient-reported outcomes

Identifiers

PMID35069810
PMCPMC8777346
OpenAlexW4205359400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.